

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 5/08, G01N 33 /50, C12Q 1 /68, A61K 39 /095, C07K 14 /22, C12N 15 /31</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/03003</b>
			(43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: <b>PCT/GB99/02205</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 July 1999 (09.07.99)		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 9814902.4 10 July 1998 (10.07.98) GB			
(71) Applicant (for all designated States except US): THE UNIVERSITY OF NOTTINGHAM [GB/GB]; University Park, Nottingham NG7 2RD (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ALA'ALDEEN, Dlawer [GB/GB]; The University of Nottingham, University Park, Nottingham NG7 2RD (GB). TODD, Ian [GB/GB]; The University of Nottingham, University Park, Nottingham NG7 2RD (GB).			
(74) Agent: WOMSLEY, Nicholas; Swindell & Pearson, 48 Friar Gate, Derby, DE1 1GY (GB).			
(54) Title: SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES AGAINST PATHOGENIC NEISSERIA			
(57) Abstract  Methods of screening for vaccine candidates, vaccines against pathogenic neisseria and intermediaries for such vaccines have been developed. Two vaccine candidates TspA and TspB have been identified and characterised which either alone or in conjunction with the vaccines provide for treatment against pathogenic neisserias in particular Neisseria meningitidis and/or Neisseria gonorrhoea.			

ATTORNEY DOCKET NUMBER: 8449-128  
SERIAL NUMBER: 09/668,724  
REFERENCE: CY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Description**

**5**

**10**

**15**

**20**

**25**

**30**

**35**

**40**

**45**

**50**

**55**

5

1

SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES  
AGAINST PATHOGENIC NEISSERIA

10

The present invention relates to vaccines for Pathogenic *Neisseria*, and particularly but not exclusively to a screening system for the identification of CD4<sup>+</sup> T-cell stimulating vaccines in Pathogenic *Neisseria*.

15

20

The term "vaccine candidates" is used to refer to peptides which may prove, upon further study, to exhibit some form of vaccine property. In particular, the vaccine candidates discussed below are peptides which stimulate CD4<sup>+</sup> T-cells (T-cells with CD4 marker on them).

25

The generic name Pathogenic *Neisseria* covers the pathogenic organisms *Neisseria meningitidis* and *Neisseria gonorrhoea*.

30

*Neisseria meningitidis* (the meningococcus) causes meningitis and overwhelming septicaemia that can kill within hours. It also causes outbreaks of meningococcal disease. *Neisseria gonorrhoea* (the gonococcus) causes gonorrhoea and other invasive diseases, e.g. pelvic inflammatory diseases and septic arthritis.

35

40

45

Although the two neisserial species (*N. meningitidis* and *N. gonorrhoea*) have evolved to colonise and invade different anatomical sites of the human body, they are strongly related and share extensive amount of genetic, immunochemical and other biological properties. They are believed to have evolved from a common ancestor, a view strongly supported by the recently released respective genomic sequence data. The outer membrane structure of the two organisms are very similar with a vast number of outer membrane proteins, including some vaccine candidates, being virtually identical. Recent data suggest that vaccines based on conserved (cross-reactive) immunogenic proteins may protect against both organisms.

50

The mechanisms responsible for the development of natural immunity

55

5

2

10

to meningococcal disease remain unclear and the currently available capsular polysaccharide (CPS)-based vaccines provide only serogroup-specific and short-lived protection and are not effective in children under two years of age. Additionally, the CPS of serogroup B meningococci, which are responsible for the majority of cases in Europe and America, is only very poorly immunogenic in humans, generating mainly IgM antibodies.

15

20

Recovery from meningococcal infection is followed by long lasting immunity and, in the absence of immunodeficiencies, second episodes of meningitis (with homologous or heterologous strains) are extremely rare. This fact indicates that there are non-capsular (cross-reactive) antigens that can stimulate T-cell memory and thus generate a long-lasting and cross-protective immunity.

25

30

35

40

To achieve an efficient humoral immune response resulting in the production of high affinity IgG antibodies and the generation of memory B lymphocytes (B-cells), help from T lymphocytes (T-cells) is required. However, helper T-cells respond to peptide antigens associated with class II molecules of the major histocompatibility complex (MHC - designated HLA in humans) on the surface of antigen presenting cells. Therefore, they will not be stimulated by purified polysaccharide vaccines (T-cell independent B-cell immunogens). To trigger a strong memory T-cell response when the host confronts the virulent organism, the target B-cell epitope should be expressed along with helper T-cell stimulating epitopes. Identification and characterisation of the peptide epitopes that can best stimulate meningococcal specific CD4<sup>+</sup> T-cells is an important part of the present invention. An ideal meningococcal vaccine must consist of a carefully selected mixture of well-characterised B- and T-cell antigens capable of generating a long lasting immunity.

45

50

It appears that meningococcal vaccine candidates will also have the potential to protect against gonococcal disease.

55

In the following description the term T-cell clone is defined as the

5

3

population of cells which originate from a single T cell.

10

In a first aspect, the present invention provides a method of generating T-cell lines and clones specific to neisserial proteins, the method comprising isolating peripheral blood mononuclear cells (PBMCs) from the peripheral blood of normal donors and patients recovering from neisserial disease, culturing the PBMCs with neisserial proteins with or without a proliferation stimulant for a prescribed period, stimulating proliferation of T-cell lines and clones which are specific to neisserial proteins, and maintaining same by regular stimulation.

15

20

The neisserial proteins are preferably prepared from *Neisseria meningitidis* and/or *Neisseria gonorrhoea* grown under iron restrictions to induce the expression of iron-regulated proteins.

25

30

The peripheral blood is preferably obtained from naturally infected patients at different stages of illness. Preferably the stages include an acute stage (on admission), early convalescence (seven days after admission), late convalescence (six weeks after discharge) and after full recovery (3 months and twelve months after discharge).

35

Preferably the peripheral blood is heparinised or treated with EDTA and the PBMCs may be isolated therefrom by centrifugation.

40

Preferably the PBMCs are initially cultured in medium containing human serum. Preferably the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period. Preferably the predetermined period is 3-10 days and may be 5 days.

45

50

Preferably IL-2 stimulates the proliferation of the activated T-cell lines and clones. Preferably the T-cell lines and clones are maintained by weekly stimulation. The stimulation may be provided by proteins in the presence of IL-2 and feeder cells. Preferably the feeder cells are antigen presenting feeder cells and may be autologous Epstein-Barr virus transformed B-lymphocytes

55

5

4

(EBVB).

10

The specificity of the T-cell lines and clones to neisserial proteins is preferably tested prior to storing for example in liquid nitrogen. Preferably the specificity is tested by measurement of tritiated thymidine incorporation in response to stimulation with neisserial proteins compared to irrelevant

15

antigens. Such an irrelevant antigen may be tetanus toxoid. The phenotypes of the T-cell lines and clones are preferably also assessed using flow cytometry and specific monoclonal antibodies. The antibodies are preferably CD4<sup>+</sup>, CD8<sup>+</sup> and  $\alpha/\beta$ - and  $\gamma/\delta$ - T-cell receptor (TCR) specific monoclonal antibodies.

20

In a second aspect the present invention provides a method of detecting CD4<sup>+</sup> T-cell stimulating proteins, the method comprising fractionating neisserial proteins and testing the ability of said proteins to stimulate proliferation of T-cell lines and clones.

25

Preferably the T-cell lines and clones are *Neisseria* specific T-cell lines and clones generated according to the method of the first aspect of the invention, as set out above.

30

The proteins may be fractionated by SDS-PAGE. The fractions are preferably tested for their ability to stimulate the individual T-cell lines and clones. Preferably fractions containing T-cell stimulants are further characterised by SDS-PAGE.

35

40

Polyclonal antibodies may be raised to the T-cell stimulating fraction proteins. The antibodies are preferably used to screen a genomic meningococcal and/or gonococcal expression library. Preferably the expression library is a  $\lambda$ ZapII library. Isolated neisserial polypeptides which react with the antibodies and their respective DNA fragments are preferably further characterised and sequenced.

45

50

In a third aspect, the present invention provides a method of detecting

55

CD4<sup>+</sup> T-cell stimulating recombinant proteins, the method comprising screening a genomic meningococcal or gonococcal expression library for recombinant proteins which stimulate T-cell lines and clones.

Preferably the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method of the first aspect of the invention, as set out above.

Preferably the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a strain of *Neisseria meningitidis* or a strain of *Neisseria gonorrhoea*. Preferably a representative pool of recombinant pBluescript SKII plasmid are excised from the phage library and transformed into *E. coli* strain XL1-Blue. Preferably the plasmids are excised into XL1-Blue using a helper phage.

The transformed *E. coli* are preferably cultured in a medium which may contain ampicillin. Meningococcal or gonococcal protein expression is preferably induced by isopropyl-b-D-thio-galactoside.

Preferably the bacteria are heat-killed and sonicated before adding to antigen presenting cells. The expressed proteins are preferably tested for their ability to stimulate the individual T-cell lines and clones. Preferably CD4<sup>+</sup> T-cell stimulating bacterial cultures are identified and subcultured. The subcultures are preferably rescreened for T-cell stimulation.

Preferably the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and may be further characterised.

Alternatively the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a meningococcal or gonococcal genomic lambda phage display library.

In a fourth aspect the present invention provides a method of detecting



5

6

10

CD4<sup>+</sup> T-cell stimulating peptides, the method comprising screening meningococcal or gonococcal genomic phage display libraries (PDLs) to identify peptides which stimulate T-cell lines and clones.

15

Preferably the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method of the first aspect of the invention, as set out above.

20

Preferably the genomic phage display library (PDL) is generated by fragmenting bacterial DNA, cloning and packaging into bacteriophage vectors. Preferably two vectors are used. The first vector preferably displays peptides up to 1200 amino acids which are expressed at low copy numbers. The second vector preferably displays up to 415 copies of a peptide up to 50 amino acids in size.

25

30

Preferably the PDLs are amplified in respective *E.coli* hosts. The cells are preferably heat killed before testing for the ability of the peptides to stimulate the T-cell lines and clones.

35

Preferably CD4<sup>+</sup> T-cell stimulating PDL cultures are identified and subcultured. The subcultures are preferably rescreened for T-cell stimulation.

40

Preferably the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and may be further characterised.

45

In a fifth aspect the present invention provides a method of detecting CD4<sup>+</sup> T-cell stimulating recombinant proteins, using a meningococcal or gonococcal genomic lambda phage display library in accordance with the third aspect of the invention, as set out above.

50

The meningococcal or gonococcal genomic lambda phage display library is preferably constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same

55

5

7

into a pre-digested vector, and plating by infecting *E.coli*.

10

Preferably the vector is a lambda phage and is preferably  $\lambda$ prH825 vector. The amplified and digested DNA fragments are preferably packaged into the lambda phage using a lambda phage packaging kit. Preferably the restriction sites are SpeI or NotI.

15

Preferably the DNA inserts in the plaques formed are sequenced, thereby confirming that the plaques contain DNA fragments of meningococcal or gonococcal origin.

20

In a sixth aspect the present invention provides the use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2 or an active derivative thereof.

25

Preferably the polypeptide is a CD4<sup>+</sup> T-cell stimulant.

30

In a seventh aspect of the present invention there is provided a DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease, the construct comprising a sequence as shown in SEQIDNO3 or an active derivative thereof.

35

In an eighth aspect the present invention provides the use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4 or an active derivative thereof.

40

Preferably the polypeptide is a CD4<sup>+</sup> T-cell stimulant.

45

According to a further aspect, there is provided a DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease, the construct comprising a sequence as shown in SEQIDNO1, or an active derivative

50

55

5 thereof.

10 In a still further aspect the invention provides a composition for use as a vaccine against neisserial disease, the composition comprising two peptides with the amino acid sequences as shown in SEQIDNO1 and SEQIDNO2, and SEQIDNO3 and SEQIDNO4 or active derivatives thereof.

15 In a further aspect of the present invention there is provided a nucleotide sequence comprising a base sequence as shown in SEQIDNO1, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2, or an active derivative thereof.

20 In a still further aspect of the present invention there is provided a nucleotide sequence comprising a base sequence as shown in SEQIDNO3, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4, or an active derivative thereof.

25 The invention also provides a vaccine against neisserial disease, the vaccine comprising polypeptide with some or all of the amino acid sequence as shown in SEQIDNO2, or an active derivative thereof.

30 The invention provides a further vaccine against neisserial disease, the vaccine comprising polypeptide with some or all of the amino acid sequence as shown in SEQIDNO4, or an active derivative thereof.

35 According to a further aspect of the present invention there is provided a method of treatment of neisserial disease, the method comprising inducing T-cell proliferation with polypeptide comprising one or both of the or some of the amino acid sequences shown in SEQIDNO2 and SEQIDNO4, or active derivative(s) thereof.

5

10

15

20

25

30

35

40

45

50

55

5 The invention also provides a purified and isolated DNA composition comprising the sequence of SEQIDNO1 or SEQIDNO3, or an active derivative thereof.

10 Embodiments of the invention will now be described by way of example only and with reference to the accompanying drawings and sequences, in which:-

15 Fig. 1 is a graph illustrating the proliferation responses of peripheral blood mononuclear cells (PBMCs) of three patients and a healthy donor to meningococcal proteins.

20 Fig. 2 is a graph illustrating the proliferation indices of a T-cell line with fraction (SI-V) of meningococcal proteins separated by SDS PAGE.

25 Fig. 3 is a graph illustrating the proliferation indices of a T-cell line to subfractions A, B, C and D of section SI in Fig. 2, and also the proliferation index of concanavalin A (Con A) and whole cell lysate of iron-depleted meningococci (SD-).

30 SEQIDNO1 shows the nucleotide base sequence and the corresponding amino acid sequence of a gene and a polypeptide (TspA) encoded thereby, according to one aspect of the present invention;

35 SEQIDNO2 shows the polypeptide sequence of SEQIDNO1;

40 SEQIDNO3 shows the nucleotide base sequence and the corresponding amino acid sequence of a gene and a polypeptide (TspB) encoded thereby, according to another aspect of the present invention; and

45 SEQIDNO4 shows the polypeptide sequence of SEQIDNO3.

50 In order to identify meningococcal CD4<sup>+</sup> T-cell-stimulating peptides we adopted a number of different programmes all of which involve screening meningococcal peptide antigens, using meningococcal-specific CD4<sup>+</sup> T-cell lines and clones. These lines and clones have been generated over the past five years

or so, from the peripheral blood of normal donors and patients recovering from invasive meningococcal disease. *In-vitro* studies have been carried out with primed human T-cells obtained from naturally infected patients, with fresh peripheral blood samples obtained from patients at different stages of illness, namely the acute stage (on admission), early convalescence (seven days after admission), late convalescence (six weeks after discharge) and after full recovery (3 months and twelve months after discharge). T-cell lines and clones, specific to meningococcal proteins have been generated from the peripheral blood of patients recovering from meningococcal disease and healthy donors. The healthy donors were identified among twenty five volunteers by testing their peripheral blood mononuclear cells (PBMC) proliferation in response to meningococcal proteins.

#### Lymphocyte proliferation assays:

Briefly, PBMCs were isolated from heparinised blood samples by centrifugation over Histopaque (Sigma). The PBMCs were washed and cultured in 96-well tissue culture plates at  $2 \times 10^5$  cells/well in RPMI medium containing 10% human AB serum (RPMI-AB). Meningococcal proteins (from strain SD, B:15:P1,16) were prepared by growing the organism under iron restriction, to induce the expression of iron-regulated proteins which are also expressed *in vivo* [Ala'Aldeen, 1994]. The meningococcal proteins (SD-), antigens from *Candida albicans* (a recall antigen) or phytohaemagglutinin (PHA, positive control) were added to quadruplicate wells. RPMI-AB alone (with no antigen) was added to quadruplicate wells to serve as the background. After five days all cultures were pulsed with  $1\mu\text{Ci}$  of tritiated thymidine and incorporation of thymidine was determined after another eighteen hours. A positive response was defined as a PBMC proliferation index of at least 2 (see Fig. 1).

Continuous T-cell lines were established by culturing PBMCs with the meningococcal proteins and Interleukin 2 (IL-2) for five days, and activated T-cell blasts were stimulated to proliferate by a further nine days culture with IL-2 only. The lines were then maintained by weekly stimulation with proteins in

the presence of feeder cells and IL-2. Autologous Epstein-Barr virus transformed B-lymphocytes (EBVB) were used as antigen-presenting feeder cells following irradiation (6000R).

T-cell clones are defined here as the population of cells which originate from a single T-cell. Single T-cell receptors (TCRs) can engage with an extraordinary small number of peptide-HLA complexes (<10/cell) [Valitute, 1995], therefore T-cell clones will provide a highly sensitive system by which it will be possible to detect the presence of peptide antigens within mixtures of proteins. T-cell lines, specific to meningococcal antigens, were seeded at 0.3 cell/well in 96-well tissue culture plates in the presence of irradiated (non-proliferating) autologous EBVB feeder cells, plus low doses of IL-2 [Sinigaglia, 1991]. Cell growth was detected microscopically after one-two weeks and growing cells expanded further by stimulation with meningococcal proteins. All T-cell lines and clones were assessed for the phenotype (and ascertained to be CD4<sup>+</sup> T-cells), using flow cytometry and CD4, CD8 and  $\alpha/\beta$ - and  $\gamma/\delta$ - TCR-specific monoclonal antibodies. Their specificity to meningococcal proteins was tested by measurement of tritiated thymidine incorporation in response to stimulation with meningococcal proteins compared to irrelevant antigens e.g. tetanus toxoid. Large numbers of T-cell lines, oligoclones and clones from patients and normal donors have been identified and stored in liquid nitrogen until further use.

#### T-cell responses to fractionated meningococcal proteins

Meningococcal proteins were fractionated according to their molecular weights by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Two methods were used to prepare the separated proteins for addition to the T-cell cultures:

- a) Fractionated proteins were transferred onto nitrocellulose membranes which were transversely divided into five equal sections labelled SI-V, containing proteins of approximate molecular weight range >130 kDa, 70-130 kDa, 50-70 kDa, 34-50 kDa and <34 kDa, respectively. Membranes were then

solubilised with dimethyl sulphoxide and tested for their ability to stimulate T-cells using the established meningococcal specific T-cell lines. Using one of the cell lines, section SI (which contained proteins >130 kDa) caused greater T-cell proliferation than any of the other sections (Fig. 2). T-cell lines fed with either EBV-B-cells or fresh autologous PBMCs consistently gave similar results.

b) In the second method, SDS-gels containing the fractionated proteins were cut into transverse sections corresponding to the five fractions obtained by the nitrocellulose membrane method. The proteins were then directly eluted from the gel sections and purified by precipitation with organic solvents. This enabled measurement of the protein concentrations in each fraction and confirmation that differences in protein concentration were not responsible for the differences observed in Figure 2. Equivalent concentrations of purified proteins were used in lymphocyte proliferation assays. The results were consistent with those of the nitrocellulose membrane blot method (not shown).

Section SI consists of more than 12 proteins as seen on silver stained gels, ranging from 130-599 kDa (not shown). Therefore, it was subdivided into four fractions, FIA-D, and their proteins were eluted from gels as described above. The eluted proteins were tested for their ability to stimulate T-cell proliferation. As shown in Figure 3, using T-cell line of a patient, fractions FIC and D induced extremely high T-cell proliferation indices ( $\leq 30$ ), higher than fractions FIA and FIB, the whole of SI or the total SD-protein preparation. Another T-cell line showed the highest T-cell stimulation indices with fraction FIB and FIC, followed by FID, possibly reflecting the HLA specific response.

FIC was chosen for further characterisation and silver staining of SDS-gels showed that it contains four distinct protein bands (not shown). Rabbit polyclonal antibodies were raised to eluted FIC proteins and used to screen an already established genomic expression ( $\lambda$  Zap II) library. Several reactive meningococcal polypeptides and their respective DNA fragments were isolated. Two of the most promising ones (TspA and TspB) were further studied. The DNA fragments were sequenced and with help from the Sanger-released

5  
10 genomic sequences which were produced by the Neisseria Meningitidis Sequencing Group at the Sanger Centre and can be obtained from <ftp://ftp.sanger.ac.uk/pub/AAREADME.release-policy.txt>, the genes encoding these two proteins were then constructed (see SEQIDNO1-4) and cloned into high expression vectors.

15 TspA, the abbreviation for T-cell stimulating protein A identified and characterised as part of the present invention has a genetic sequence substantially as shown in SEQIDNO1 and a corresponding polypeptide sequence as shown in SEQIDNO2.

20 TspA can be used to create a vaccine against pathogenic neisseria, and in particular Neisseria meningitidis, as well as Neisseria gonorrhoea. Determination of the sequence enables the generation of antibodies using general polyclonal and/or monoclonal techniques.

25 Similarly with TspB (T-cell stimulating protein B), vaccine or a component for a combination vaccine are created using polyclonal and/or monoclonal techniques.

35 It is envisaged that an effective vaccine will be a combination vaccine comprising a plurality of different antigens including TspA and TspB.

40 The exact sequences can vary among different isolates of meningococci due to the nature of the organism and its ability to mutate any gene any time. This is a universal problem inherent with any gene of these Neisseria organisms. Equivalent genes with homologous sequences exist in *Neisseria gonorrhoea*, as detected on the recently released gonococcal genomic sequence data obtained on the Internet from Oklahoma University, U.S.A.

45  
50 Western blot experiments on TspA and TspB, using human convalescent sera, confirmed that both proteins are expressed in-vivo and stimulate B-cells following natural infection. The cloned proteins also induced strong CD4<sup>+</sup> T-



cell stimulatory effect in our T-cell proliferation assays. These suggested very clearly that they are promising vaccine candidates, and vaccines comprising one or both of these either together or with other proteins are therefore provided as part of this invention.

Finally, fractions FIB and FID, and Section SII and SV which produced net-positive T-cell stimulatory effects may consists of many T-cell stimulatory antigens (Fig. 1 and 3).

#### Detection of T-cell antigens by phage-expression cloning

The present invention also provides a robust screening system for the identification of CD4<sup>+</sup> T-cell stimulating recombinant proteins, using an expression cloning protocol, which involves screening genomic meningococcal expression libraries.

##### 1. $\lambda$ ZapII Expression Library

This method had been successfully applied in other organisms to identify helper T-cell epitopes [Sanderson, 1995; Mougneau, 1995]. Briefly, we used an existing  $\lambda$ ZapII phage library expressing genomic DNA extracted from strain SD *N. meningitidis* [Palmer, 1993 #214]. The library contains  $2 \times 10^7$  recombinants with an average size of insert of 2.3 kb (range up to 10 kb). A representative pool of recombinant pBluescript SKII plasmid were excised (*in vivo*) from the phage library and transformed into *E. coli* strain XL1-Blue, using ExAssist helper phage (Stratgene) as described previously [Ala'Aldeen, 1996; Palmer, 1993].

Transformed *E. coli* with the pBluescript plasmid carrying meningococcal genes were diluted in selective culture media (containing ampicillin) and put in 96-well microtitre plates at 20-30 transformants/wells. The plates were incubated overnight at 37°C with shaking and replicate cultures were made by splitting the overnight cultures, and the original master plates stored at 4°C.

The splits were grown in epindorfs for 2-3 hours in fresh medium to  $OD_{600}=0.3$ , then incubated for an additional 2h with 1mM isopropyl-b-D-thio-galactoside (IPTG) to induce meningococcal protein expression. Bacteria were heat-killed, sonicated and added to the antigen presenting cells, and tested for their ability to stimulate individual T-cell lines and clones. Negative controls were sonicates of the same *E. coli* strain transformed with pBluescript SKII with no meningococcal DNA insert. Strong T-cell stimulating wells were identified and their corresponding reference wells diluted and subcultured. Up to 100 single colonies (representing single organisms with single plasmids) were isolated and re-screened for T-cell stimulation. Only potent T-cell stimulants were saved and further pursued. This aspect of the present invention proved highly rewarding, and so far two, previously unknown, potent T-cell stimulating meningococcal polypeptides have been identified and further characterised.

## 2. T-cell antigen detection using phage display libraries (PDL)

Displaying foreign peptides on the surface of bacteriophages is a relatively new but well-established technology. This is different from the normal phage libraries which carry the cloned genes and express and release the proteins inside a host bacterium and not on their own outer coat. In phage display libraries, displayed peptides are encoded as DNA inserts in the structural gene for one of the viral coat proteins and will then appear on the surface of the phage capsid. There are several phage display systems available, each with specific advantages. For example, some are filamentous and others are lytic, some are used as random display libraries (non-specific) which may be used to detect mimotopes, and others are more specific genomic libraries. It is important to note that most phage display libraries have been probed with antibodies in search of specific peptides. A highly novel approach comprising a further aspect of the present invention was developed involving the use of T-cell lines/clones to screen two different meningococcal genomic PDLs to identify good T-cell stimulating peptides.

### a) T7Select1 and T7Select415 PDL

One of the novel lytic bacteriophages is Novagen's T7Select Phage Display System which is easy to use and has the capacity to display peptides up to 1200 amino acids, equivalent to 3.6 kb, with protein molecular weight over 100kDa. Such high molecular weight proteins are usually expressed at low copy numbers by T7Select1. Phage T7Select415, however, is capable of displaying up to 415 copies of a peptide up to 50 amino acids in size. Phage assembly occurs in the *E. coli* cytoplasm and mature phages are released by cell lysis. The latter process occurs within a few hours of infection, which makes the system very rapid. To create a genomic display library, meningococcal DNA will be fragmented to appropriate sizes and cloned and packaged into both T7Select1 and T7Select415 vectors as described in the Novagen's T7Select System manual [Novagen, 1996]. This dual approach allows for the screening for both large and small polypeptides.

A representative population of these PDLs expressing meningococcal proteins are diluted and distributed as oligoclones into 96-well microtitre plates. To each well, appropriate *E. coli* host strains (BL21 for T7Select415 and BLT5403 for T7Select1) will be added to amplify the diluted phage population in these wells. The plates will be split into identical duplicates, one of which will be stored as the reference, and the other heat-killed and tested for the ability to stimulate the T-cell lines/clones as described above for the  $\lambda$ ZAPII library.

b)  $\lambda$ PRH825 random meningococcal epitope display library

Another method according to the present invention involves the use of proteins and small peptides on a modified lambda capsid protein D. This protein, which is of 11 kDa with 405 copies expressed as trimers on the phage head [Sternberg, 1995; Mikawa, 1996], is capable of an efficient display of foreign peptides that are fused to its amino- or carboxy-termini [Mikawa, 1996]. This system was successfully used to display a Hepatitis C genomic cDNA library [Alter, 1995] and, more recently, to generate a randomly amplified genomic PDL of known organisms [Lambert, 1993; Kwong-Kowk, 1996; Tomei,

1993]. This involves generating randomly amplified DNA fragments of a known DNA template, using short (random) oligonucleotide primers in polymerase chain reaction (PCR). We have recently constructed a meningococcal genomic lambda phage display library by cloning randomly amplified PCR products into  $\lambda$ PRH825 vector, using two random primers, each tagged at 5' end to *SpeI* or *NotI* restriction sites to facilitate insertion into the predigested vector. Packaging amplified and digested DNA fragments into lambda phage was performed using a lambda packaging kit (Pharmacia Biotech) and plated by infection of the *E. coli* strain BB4. This yielded  $5 \times 10^7$  plaques, of which a sample of 100 pfu were randomly chosen, and their DNA inserts sequenced. Sequence alignment of the obtained sequence data with those available for *N. Meningitidis* (Sanger, Wellcome) and/or *N. Gonorrhoea*, confirmed that all the chosen plaques contained DNA fragments of meningococcal origin. The fragment sizes ranged from 100-200 bp, representing deduced peptides of up to 60 amino acids long. This PDL was prepared and established in IRBM for use in the identification of CD4<sup>+</sup> T-cell stimulating recombinant peptides, using the same cloning technique described for the  $\lambda$ ZapII phage system.

Several selection criteria have been adopted to focus the search for relevant, potent and promiscuous T-cell epitopes.

Initially, only candidate peptides, which are likely to contain multiple T-cell epitopes that are immunogenic for CD4<sup>+</sup> Th-cells (not CD8<sup>+</sup> T-cells) and presented on MHC class II (HLA-DR, DQ or DP in humans) were studied. Only T-helper (Th) antigens, that bind to a number of widely ranging HLA-types, were selected. It will be determined whether each patient's CD4<sup>+</sup> Th-response to a candidate meningococcal peptide is due to an established memory Th population (CD45RO<sup>+</sup>) or to activation of naive T-cells (CD45RA<sup>+</sup>). Peptide candidates which activate either the Th2 subset of CD4<sup>+</sup> T-cell or the Th1 subset are selected. The therapeutic efficacy of both Th1 and Th2-inducing candidate peptides will be evaluated. T-cell clones specific for candidate antigens will be amplified and used to identify the individual T-cell epitopes.

5  
10  
15  
20  
25  
In order to identify and then characterise core epitopes of each candidate peptide, progressively smaller fragments of the DNA will be cloned, expressed and further examined for T-cell stimulation. To define epitopes more accurately, short overlapping peptides representing the defined T-cell stimulating subunits are synthesised and re-examined. Then N- and C-terminal truncated analogs of the most immunogenic peptide fragment are synthesised and tested likewise. Finally, alanine scanning mutational analysis will be employed to identify critical amino acid positions responsible for both TCR contact and HLA-class II contact. Here, a series of peptide analogs of the core epitope identified after N- and C-terminal truncation are synthesised, each with a single alanine substituted at successive amino acid positions, and effects on T-cell immunogenicity and on HLA-binding are assessed [Nelson, 1996]. The isotype of class II HLA molecule restriction specificity will be identified for each T-cell clone by antibody blocking experiments.

30  
35  
As a part of the characterisation of the identified proteins, the diversity of these proteins among various strains of meningococci is studied. A large collection of clinical isolates of meningococci have been prepared, the proteins of these strains when purified (from the gels or clones), and tested for T-cell stimulatory capacity and characterised in a way similar to that used for strain SD will provide further vaccine candidates. Proteins that are expressed in all or more of these stains will be focused on.

#### Identification of HLA restriction

40  
45  
50  
55  
To determine whether different HLA class II molecules present different parts of individual proteins, one of two methods are used. The protein sub-fragments and their overlapping peptides described above will be tested for their capacity to stimulate T-cell clones generated from different individuals (volunteers or patients). Alternatively, lymphocyte donors will be HLA typed, and the association of responsiveness to particular proteins (or epitopes) and certain alleles of HLA-DR, -DQ or -DP determined.

5

10

15

20

25

A central aim is to identify T-cell immunogens of *N. meningitidis* which will stimulate T-cell help for the production of protective anti- meningococcal antibodies. Having identified dominant T-cell antigens amongst the proteins, their ability to stimulate T-cell help for antibody production is investigated *in vivo* in animals and in an *in vitro* immunisation system which has been established and optimised in our laboratories [Davenport, 1992]. Protein fragments or peptides that stimulate T-cells from individuals covering a range of HLA types are studied for the presence of B-cell epitopes. If the protein contains B-cell epitopes then antibodies from individuals naturally immune to meningococcal disease should recognise these proteins in immunoblots or ELISA. If no B-cell epitopes are recognised then the identified T-cell epitopes will be conjugated to previously characterised B-cell immunogens such as the meningococcal capsular polysaccharides, the class (1, 2/3) proteins, the transferrin binding proteins ... etc.

30

35

40

45

50

55

Whilst endeavouring in the foregoing specification to draw attention to the features of the invention believed to be of particular importance it should be understood that the Applicant claims protection in respect of any patentable feature hereinbefore referred to and/or shown in the drawings whether or not particular emphasis has been placed thereon.

## Claims

5

10

15

20

25

30

35

40

45

50

55

5

20

CLAIMS

10

1. A method of generating T-cell lines and clones specific to neisserial proteins, the method comprising isolating peripheral blood mononuclear cells (PBMCs) from the peripheral blood of normal donors and patients recovering from neisserial disease, culturing the PBMCs with neisserial proteins with or without a proliferation stimulant for a prescribed period, stimulating proliferation of T-cell lines and clones which are specific to neisserial proteins, and maintaining same by regular stimulation.

15

20

2. A method as claimed in claim 1, characterised in that the neisserial proteins are prepared from *Neisseria meningitidis* and/or *Neisseria gonorrhoea* grown under iron restrictions to induce the expression of iron-regulated proteins.

25

30

3. A method as claimed in any preceding claim, characterised in that the peripheral blood is obtained from naturally infected patients at different stages of illness.

35

4. A method as claimed in claim 3, characterised in that the stages include an acute stage (on admission), early convalescence (seven days after admission), late convalescence (six weeks after discharge) and after full recovery (3 months and twelve months after discharge).

40

5. A method as claimed in any preceding claim, characterised in that the peripheral blood is heparinised or treated with ESTA.

45

6. A method as claimed in any preceding claim, characterised in that the PBMCs are isolated from the blood by centrifugation.

50

7. A method as claimed in any preceding claim, characterised in that the PBMCs are initially cultured in medium containing human serum.

55



5

21

10

8. A method as claimed in any preceding claim, characterised in that the PBMCs are cultured with the neisserial proteins and Interleukin 2 (IL-2) for a predetermined period.

15

9. A method as claimed in claim 8, characterised in that the predetermined period is 3-10 days and may be 5 days.

20

10. A method as claimed in any of claims 8 or 9, characterised in that IL-2 stimulates the proliferation of the activated T-cell lines and clones.

25

11. A method as claimed in claim 10, characterised in that the T-cell lines and clones are maintained by weekly stimulation.

30

12. A method as claimed in claim 10 or claim 11, characterised in that the stimulation is provided by proteins in the presence of IL-2 and feeder cells.

35

13. A method as claimed in claim 12, characterised in that the feeder cells are antigen presenting feeder cells and may be autologous Epstein-Barr virus transformed B-lymphocytes (EBVB).

40

14. A method as claimed in any preceding claim, characterised in that the specificity of the T-cell lines and clones to neisserial proteins is tested prior to storing for example in liquid nitrogen.

45

15. A method as claimed in claim 14, characterised in that the specificity is tested by measurement of tritiated thymidine incorporation in response to stimulation with neisserial proteins compared to irrelevant antigens.

50

16. A method as claimed in claim 15, characterised in that an irrelevant antigen is tetanus toxoid.

55

17. A method as claimed in any preceding claim, characterised in that the phenotype of the T-cell lines and clones are also assessed using flow cytometry

and specific monoclonal antibodies.

18. A method as claimed in claim 17, characterised in that the antibodies are CD4<sup>+</sup>, CD8<sup>+</sup> and  $\alpha/\beta$ - and  $\gamma/\delta$ - T-cell receptor (TCR) specific monoclonal antibodies.

19. A method of detecting CD4<sup>+</sup> T-cell stimulating proteins, the method comprising fractionating neisserial proteins and testing the ability of said proteins to stimulate proliferation of T-cell lines and clones.

20. A method as claimed in claim 19, characterised in that the T-cell lines and clones are Neisseria specific T-cell lines and clones generated according to the method as claimed in any of claims 1 to 18.

21. A method as claimed in any of claims 19 to 20, characterised in that the proteins are fractionated by SDS-PAGE.

22. A method as claimed in any of claims 19 to 21, characterised in that the fractions are tested for their ability to stimulate the individual T-cell lines and clones.

23. A method as claimed in claim 22, characterised in that fractions containing T-cell stimulants are further characterised by SDS-PAGE.

24. A method as claimed in any of claims 19 to 23, characterised in that polyclonal antibodies are raised to the T-cell stimulating fraction proteins.

25. A method as claimed in claim 24, characterised in that the antibodies are used to screen a genomic meningococcal and/or gonococcal expression library.

26. A method as claimed in claim 25, characterised in that the expression library is a  $\lambda$ ZapII library.

5

10

15

20

25

30

35

40

45

50

55

27. A method as claimed in claim 25 or claim 26, characterised in that isolated neisserial polypeptides which react with the antibodies and their respective DNA fragments are further characterised and sequenced.

28. A method of detecting CD4<sup>+</sup> T-cell stimulating recombinant proteins, the method comprising screening a genomic meningococcal or gonococcal expression library for recombinant proteins which stimulate T-cell lines and clones.

29. A method as claimed in claim 28, characterised in that the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method of any of claims 1 to 18.

30. A method as claimed in claim 28 or claim 29, characterised in that the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a strain of *Neisseria meningitidis* or a strain of *Neisseria gonorrhoea*.

31. A method as claimed in claim 30, characterised in that a representative pool of recombinant pBluescript SKII plasmid are excised from the phage library and transformed into *E.coli* strain XL1-Blue.

32. A method as claimed in claim 31, characterised in that the plasmids are excised into XL1-Blue using a helper phage.

33. A method as claimed in claim 31 or claim 32, characterised in that the transformed *E.coli* are cultured in a medium which may contain ampicillin.

34. A method as claimed in any of claims 28 to 33, characterised in that meningococcal or gonococcal protein expression is induced by isopropyl-b-D-thio-galactoside.

35. A method as claimed in any of claims 28 to 34, characterised in that the

5

bacteria are heat-killed and sonicated before adding to antigen presenting cells.

10

36. A method as claimed in any of claims 28 to 35, characterised in that the expressed proteins are tested for their ability to stimulate the individual T-cell lines and clones.

15

37. A method as claimed in any of claims 28 to 36, characterised in that CD4<sup>+</sup> T-cell stimulating bacterial cultures are identified and subcultured.

20

38. A method as claimed in claim 37, characterised in that the subcultures are preferably rescreened for T-cell stimulation.

25

39. A method as claimed in claim 37 or claim 38, characterised in that the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and are further characterised.

30

40. A method as claimed in any of claims 28 or 29, characterised in that the genomic meningococcal or gonococcal expression library is a  $\lambda$ ZapII phage library expressing genomic DNA extracted from a meningococcal or gonococcal genomic lambda phage display library.

35

41. A method of detecting CD4<sup>+</sup> T-cell stimulating peptides, the method comprising screening meningococcal or gonococcal genomic phage display libraries (PDLs) to identify peptides which stimulate T-cell lines and clones.

40

42. A method as claimed in claim 41, characterised in that the T-cell lines and clones are meningococcal and/or gonococcal specific T-cell lines and clones generated according to the method as claimed in any of claims 1 to 18.

45

43. A method as claimed in any of claims 41 to 42, characterised in that the genomic phage display library (PDL) is generated by fragmenting bacterial DNA, cloning and packaging into bacteriophage vectors.

50

55

5

44. A method as claimed in claim 43, characterised in that two vectors are used.

10

45. A method as claimed in claim 44, characterised in that the first vector displays peptides up to 1200 amino acids which are expressed at low copy numbers.

15

46. A method as claimed in claim 44 or claim 45, characterised in that the second vector preferably displays up to 415 copies of a peptide up to 50 amino acids in size.

20

47. A method as claimed in any of claims 41 to 46, characterised in that the PDLs are amplified in respective *E.coli* hosts.

25

48. A method as claimed in any of claims 41 to 47, characterised in that the cells are heat killed before testing for the ability of the peptides to stimulate the T-cell lines and clones.

30

49. A method as claimed in any of claims 41 to 48, characterised in that CD4<sup>+</sup> T-cell stimulating PDL cultures are identified and subcultured.

35

50. A method as claimed in claim 49, characterised in that the subcultures are rescreened for T-cell stimulation.

40

51. A method as claimed in any of claims 41 to 50, characterised in that the CD4<sup>+</sup> T-cell stimulants are identified by sequencing and are further characterised.

45

52. A method of detecting CD4<sup>+</sup> T-cell stimulating recombinant proteins, using a meningococcal or gonococcal genomic lambda phage display library in accordance with any of claims 28 to 40.

50

53. A method as claimed in claim 52, characterised in that the

55

5

10

15

20

25

30

35

40

45

50

55

meningococcal or gonococcal genomic lambda phage display library is constructed by cloning randomly amplified PCR products using two random primers, each tagged at 5' end to restriction sites, inserting same into a pre-digested vector, and plating by infecting *E.coli*.

54. A method as claimed in claim 53, characterised in that the vector is a lambda phage.

55. A method as claimed in claim 54, characterised in that the vector is  $\lambda$ prH825 vector.

56. A method as claimed in claim 54 or 55, characterised in that the amplified and digested DNA fragments are packaged into the lambda phage using a lambda phage packaging kit.

57. A method as claimed in any of claims 53 to 56, characterised in that the restriction sites are *SpeI* or *NotI*.

58. A method as claimed in any of claims 52 to 57, characterised in that the DNA inserts in the plaques formed are sequenced, thereby confirming that the plaques contain DNA fragments of meningococcal or gonococcal origin.

59. Use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2 or an active derivative thereof.

60. A polypeptide as claimed in claim 59, characterised in that the polypeptide is a CD4<sup>+</sup> T-cell stimulant.

61. A DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease the construct comprising a sequence as shown in SEQIDNO3 or an active derivative thereof.

5

10

15

20

25

30

35

40

45

50

55

62. Use of a polypeptide in the manufacture of a vaccine against neisserial disease, the peptide comprising an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4 or an active derivative thereof.

63. A polypeptide as claimed in claim 62, characterised in that the polypeptide is a CD4<sup>+</sup> T-cell stimulant.

64. A DNA construct for use in the manufacture of a medicament for the treatment of neisserial disease, the construct comprising a sequence as shown in SEQIDNO1, or an active derivative thereof.

65. A composition for use as a vaccine against neisserial disease, the composition comprising two peptides with the amino acid sequences as shown in SEQIDNO1 and SEQIDNO2, and SEQIDNO3 and SEQIDNO4 or active derivatives thereof.

66. A nucleotide sequence comprising a base sequence as shown in SEQIDNO1, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO1 and SEQIDNO2, or an active derivative thereof.

67. A nucleotide sequence comprising a base sequence as shown in SEQIDNO3, or an active derivative thereof, the sequence coding for a polypeptide having an amino acid sequence as shown in SEQIDNO3 and SEQIDNO4, or an active derivative thereof.

68. A vaccine against neisserial disease, the vaccine comprising polypeptide with some or all of the amino acid sequence as shown in SEQIDNO2.

69. A vaccine against neisserial disease, the vaccine comprising polypeptide with some or all of the amino acid sequence as shown in SEQIDNO4.

70. A method of treatment of neisserial disease, the method comprising

5

28

10

inducing T-cell proliferation with polypeptide comprising one or both the or some of the amino and sequences shown in SEQIDNO2 and SEQIDNO4, or active derivative(s) thereof.

15

71. A purified and isolated DNA composite comprising the sequence shown in SEQIDNO1, or an active derivative thereof.

20

72. A purified and isolated DNA composition comprising the sequence shown in SEQIDNO3, or an active derivative thereof.

25

73. A methodology substantially as hereinbefore described with reference to the accompany drawings and sequences.

30

74. Use of a polypeptide substantially as hereinbefore described with reference to the accompany drawings and sequences.

35

75. A DNA construct substantially as hereinbefore described with reference to the accompany drawings and sequences.

40

76. A composition substantially as hereinbefore described with reference to the accompany drawings and sequences.

45

77. A nucleotide sequence substantially as hereinbefore described with reference to the accompany drawings and sequences.

50

78. A vaccine substantially as hereinbefore described with reference to the accompany drawings and sequences.

55

79. A method of treatment substantially as hereinbefore described with reference to the accompany drawings and sequences.

80. Any novel subject matter or combination including novel subject matter disclosed herein, whether or not within the scope of or relating to the same



5

29

invention as any of the preceding claims.

10

15

20

25

30




35

40

45

50

55

**FIG. 1****FIG. 2****FIG. 3**

SEQUENCE LISTING

- (1) Information for SEQIDNO1:
  - (a) Sequence Characteristics:
    - (i) Length : 2761 base pairs
    - (ii) Type : Nucleic acid
    - (iii) Strandedness : Double
  - (b) Molecule type : DNA (genomic)
  - (c) Original Source:
    - (i) Organism : *Neisseria meningitidis*
    - (ii) Strain : SD, serogroup B (B:15:Pl.16)

(2) Information for SEQIDNO2:

(a) Sequence Characteristics:

- (i) Length : 880 amino acids
- (ii) Type : amino acid
- (iii) Topology : linear

(b) Molecule type : protein

(c) Original Source:

- (i) Organism : *Neisseria meningitidis*
- (ii) Strain : SD, serogroup B (B:15:Pl.16)

(3) Information for SEQIDNO3:

(a) Sequence Characteristics:

- (i) Length : 1647 base pairs
- (ii) Type : Nucleic acid
- (iii) Strandedness : Double

(b) Molecule type : DNA (genomic)

(c) Original Source:

- (i) Organism : *Neisseria meningitidis*
- (ii) Strain : SD, serogroup B (B:15:Pl.16)

(4) Information for SEQIDNO4:

(a) Sequence Characteristics:

- (i) Length : 548 amino acids
- (ii) Type : amino acid
- (iii) Topology : linear

(b) Molecule type : protein

(c) Original Source:

- (i) Organism : *Neisseria meningitidis*
- (ii) Strain : SD, serogroup B (B:15:Pl.16)

## SEQUENCE LISTING

<110> The University of Nottingham

<120> Screening of Neisserial Vaccine Candidates and Vaccines  
against Pathogenic Neisseria.

<130> NW/6943INT

<140> PCT/GB99/02205

<141> 1999-07-09

<150> 9814902.4

<151> 1998-07-10

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 2761

<212> DNA

<213> Neisseria meningitidis

<220>

<221> CDS

<222> (119)..(2761)

<400> 1

gattgatgca aatatgcaca gatgtttttg aaaaaagatg gagatatgtc ataatgtgta 60

aaaacggcga atgattgccg tttaaaatgt ggcgggcggtc ggtacattca catattaa 118

atg ccc gcc gcc cga ctg ccc cgc cga tgc ccg atg atg acg aaa ttt 166

Met Pro Ala Gly Arg Leu Pro Arg Arg Cys Pro Met Met Thr Lys Phe

1 5 10 15

aca gac tgt acg cgg tca aac cgt att cag cgg cca acc cac agg gga 214

Thr Asp Cys Thr Arg Ser Asn Arg Ile Gln Pro Pro Thr His Arg Gly

20 25 30

tac atc ttg aaa aac aac aga caa atc aaa ctg att gcc gcc tcc gtc 262

Tyr Ile Leu Lys Asn Asn Arg Gln Ile Lys Leu Ile Ala Ala Ser Val

35 40 45

gca gtt gcc gca tcc ttt cag gca cat gct gga ctg ggc gga ctg aat 310

Ala Val Ala Ala Ser Phe Gln Ala His Ala Gly Leu Gly Gly Leu Asn

50 55 60

atc cag tcc aac ctt gac gaa ccc ttt tcc gcc agc att acc gta acc 358  
 Ile Gln Ser Asn Leu Asp Glu Pro Phe Ser Gly Ser Ile Thr Val Thr  
 65 70 75 80

gcc gaa gaa gcc aaa gcc ctg cta gcc gcc gcc agc gtt acc gtt tcc 406  
 Gly Glu Glu Ala Lys Ala Leu Leu Gly Gly Gly Ser Val Thr Val Ser  
 85 90 95

gaa aaa gcc ctg acc gcc aaa gtc cac aag ttg gcc gac aaa gcc gtc 454  
 Glu Lys Gly Leu Thr Ala Lys Val His Lys Leu Gly Asp Lys Ala Val  
 100 105 110

att gcc gtt tct tcc gaa cag gca gtc cgc gat ccc gtc ctg gta ttc 502  
 Ile Ala Val Ser Ser Glu Gln Ala Val Arg Asp Pro Val Leu Val Phe  
 115 120 125

cgc atc gcc gca gcc gca cag gta cgc gaa tac acc gcc atc ctt gat 550  
 Arg Ile Gly Ala Gly Ala Gln Val Arg Glu Tyr Thr Ala Ile Leu Asp  
 130 135 140

cct gtc gcc tac tcc ccc aaa acc aaa tct gca ctt tca gac gcc aag 598  
 Pro Val Gly Tyr Ser Pro Lys Thr Lys Ser Ala Leu Ser Asp Gly Lys  
 145 150 155 160

aca cac cgc aaa acc gct ccg aca gca gag tcc caa gaa aat caa aac 646  
 Thr His Arg Lys Thr Ala Pro Thr Ala Glu Ser Gln Glu Asn Gln Asn  
 165 170 175

gcc aaa gcc ctc cgc aaa acc gat aaa aaa gac agc gcg aac gca gcc 694  
 Ala Lys Ala Leu Arg Lys Thr Asp Lys Lys Asp Ser Ala Asn Ala Ala  
 180 185 190

gtc aaa ccg gcg tac aac gcc aaa acc cat acc gtc cgc aaa gcc gaa 742  
 Val Lys Pro Ala Tyr Asn Gly Lys Thr His Thr Val Arg Lys Gly Glu  
 195 200 205

acg gtc aaa cag att gcc gcc gcc atc cgc ccg aaa cac ctg acg ctc 790  
 Thr Val Lys Gln Ile Ala Ala Ala Ile Arg Pro Lys His Leu Thr Leu  
 210 215 220

gaa cag gtt gcc gat gcg ctg ctg aag gca aac cca aat gtt tcc gca 838  
 Glu Gln Val Ala Asp Ala Leu Leu Lys Ala Asn Pro Asn Val Ser Ala  
 225 230 235 240

cac gcc aga ctg cgt gcg gcc agc gtc ctt cac att ccg aat ctg aac 886  
 His Gly Arg Leu Arg Ala Gly Ser Val Leu His Ile Pro Asn Leu Asn  
 245 250 255



agg atc aaa gcg gaa caa ccc aaa ccg caa acg gcg aaa ccc aaa gcc	934
Arg Ile Lys Ala Glu Gln Pro Lys Pro Gln Thr Ala Lys Pro Lys Ala	
260 265 270	
gaa acc gca tcc atg ccg tcc gaa ccg tcc aaa cag gca acg gta gag	982
Glu Thr Ala Ser Met Pro Ser Glu Pro Ser Lys Gln Ala Thr Val Glu	
275 280 285	
aaa ccg gtt gaa aaa cct gaa gca aaa gtt gcc gcg ccc gaa gca aaa	1030
Lys Pro Val Glu Lys Pro Glu Ala Lys Val Ala Ala Pro Glu Ala Lys	
290 295 300	
gcg gaa aaa ccg gcc gtt cga ccc gaa cct gta ccc gct gca aat act	1078
Ala Glu Lys Pro Ala Val Arg Pro Glu Pro Val Pro Ala Ala Asn Thr	
305 310 315 320	
gcc gca tcc gaa acc gct gcc gaa tcc gcc ccc caa gaa gcc gcc gct	1126
Ala Ala Ser Glu Thr Ala Ala Glu Ser Ala Pro Gln Glu Ala Ala Ala	
325 330 335	
tct gcc atc gac acg ccg acc gac gaa acc ggt aac gcc gtt tcc gaa	1174
Ser Ala Ile Asp Thr Pro Thr Asp Glu Thr Gly Asn Ala Val Ser Glu	
340 345 350	
cct gtc gaa cag gtt tcc gcc gaa gaa gaa acc gaa agc gga ctg ttc	1222
Pro Val Glu Gln Val Ser Ala Glu Glu Glu Thr Glu Ser Gly Leu Phe	
355 360 365	
ggc ggt tcc tac acc ttg ctg ctt gcc ggc gga ggc gcg gca ttg atc	1270
Gly Gly Ser Tyr Thr Leu Leu Leu Ala Gly Gly Gly Ala Ala Leu Ile	
370 375 380	
gcc ctg ctg ctg ctt ttg cgc ctt gcc caa tcc aaa cgc gcg cgc cgt	1318
Ala Leu Leu Leu Leu Leu Arg Leu Ala Gln Ser Lys Arg Ala Arg Arg	
385 390 395 400	
acc gaa gaa tcc gtc ctt gag gaa gag cct gac ctt gac gac gcg gca	1366
Thr Glu Glu Ser Val Pro Glu Glu Glu Pro Asp Leu Asp Asp Ala Ala	
405 410 415	
gac gac ggc ata gaa atc acc ttt gcc gaa gtc gaa act ccg gca acg	1414
Asp Asp Gly Ile Glu Ile Thr Phe Ala Glu Val Glu Thr Pro Ala Thr	
420 425 430	
ccc gaa ccc gct ccg aaa aac gat gta aac gac aca ctt gcc tta gat	1462
Pro Glu Pro Ala Pro Lys Asn Asp Val Asn Asp Thr Leu Ala Leu Asp	
435 440 445	

ggg gaa tct gaa gaa gag ttg tcy gca aaa caa acg ttc gat gtc gaa	1510
Gly Glu Ser Glu Glu Glu Leu Ser Ala Lys Gln Thr Phe Asp Val Glu	
450 455 460	
acc gat acg cct tcc aac cgc atc gat ttg gat ttc gac agc ctg gca	1558
Thr Asp Thr Pro Ser Asn Arg Ile Asp Leu Asp Phe Asp Ser Leu Ala	
465 470 475 480	
gcc gcg caa aac ggc att tta tcc ggc gca ctt acg cag gat gaa gaa	1606
Ala Ala Gln Asn Gly Ile Leu Ser Gly Ala Leu Thr Gln Asp Glu Glu	
485 490 495	
acc caa aaa cgc gcg gat gcc gat tgg aac gcc atc gaa tcc aca gac	1654
Thr Gln Lys Arg Ala Asp Ala Asp Trp Asn Ala Ile Glu Ser Thr Asp	
500 505 510	
agc gtg tac gag ccc gag acc ttc aac ccg tac aac cct gtc gaa atc	1702
Ser Val Tyr Glu Pro Glu Thr Phe Asn Pro Tyr Asn Pro Val Glu Ile	
515 520 525	
gtc atc gac acg ccc gaa ccg gaa tct gtc gcc caa act gcc gaa aac	1750
Val Ile Asp Thr Pro Glu Pro Glu Ser Val Ala Gln Thr Ala Glu Asn	
530 535 540	
aaa ccg gaa acc gtc gat acc gat ttc tcc gac aac ctg ccc tca aac	1798
Lys Pro Glu Thr Val Asp Thr Asp Phe Ser Asp Asn Leu Pro Ser Asn	
545 550 555 560	
aac cat atc ggc aca gaa gaa aca gct tcc gca aaa cct gcc tca ccc	1846
Asn His Ile Gly Thr Glu Glu Thr Ala Ser Ala Lys Pro Ala Ser Pro	
565 570 575	
tcc gga ctg gca ggc ttc ctg aag gct tcc tcy ccc gaa acc atc ttg	1894
Ser Gly Leu Ala Gly Phe Leu Lys Ala Ser Ser Pro Glu Thr Ile Leu	
580 585 590	
gaa aaa aca gtt gcc gaa gtc caa aca ccg gaa gag ttg cac gat ttc	1942
Glu Lys Thr Val Ala Glu Val Gln Thr Pro Glu Glu Leu His Asp Phe	
595 600 605	
ctg aaa gtg tac gaa acc gat gcc gtc gcg gaa act gcg cct gaa acg	1990
Leu Lys Val Tyr Glu Thr Asp Ala Val Ala Glu Thr Ala Pro Glu Thr	
610 615 620	
ccc gat ttc aac gcc gcc gca gac gat ttg tcc gca ttg ctt caa cct	2038
Pro Asp Phe Asn Ala Ala Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro	
625 630 635 640	

gcc gaa gca ccg tcc gtt gag gaa aat ata acg gaa acc gtt gcc gaa	2086
Ala Glu Ala Pro Ser Val Glu Glu Asn Ile Thr Glu Thr Val Ala Glu	
645 650 655	
aca ccc gac ttc aac gcc acc gca gac gat ttg tcc gca tta ctt caa	2134
Thr Pro Asp Phe Asn Ala Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln	
660 665 670	
cct tct gaa gta cct gcc gtt gag gaa aat gca gcg gaa atc gtt gcc	2182
Pro Ser Glu Val Pro Ala Val Glu Glu Asn Ala Ala Glu Ile Val Ala	
675 680 685	
gat gat ttg tcc gca ctg ttg caa cct gct gaa gca ccg gct gtt gag	2230
Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Ala Pro Ala Val Glu	
690 695 700	
gaa aat gta acg gaa act gtt gcc gaa acg tcc gac ttc cac acc gcc	2278
Glu Asn Val Thr Glu Thr Val Ala Glu Thr Ser Asp Phe His Thr Ala	
705 710 715 720	
gca gac gat ttg tcc gca ctg ttg caa cct gct gaa gta ccg gcc gtt	2326
Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Val Pro Ala Val	
725 730 735	
gag gaa aat gta acg aaa acc gtt gcc gaa ata cct gat ttc aac gcc	2374
Glu Glu Asn Val Thr Lys Thr Val Ala Glu Ile Pro Asp Phe Asn Ala	
740 745 750	
acc gca gac gat ttg tcc gca tta ctt caa cct tct gaa gta ccg gcc	2422
Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ser Glu Val Pro Ala	
755 760 765	
gtt gag gaa aat gca gcg gaa atc act ttg gaa acg cct gat tcc aac	2470
Val Glu Glu Asn Ala Ala Glu Ile Thr Leu Glu Thr Pro Asp Ser Asn	
770 775 780	
acc tct gag gca gac gct ttg ccc gac ttc ctg aaa gac ggc gag gag	2518
Thr Ser Glu Ala Asp Ala Leu Pro Asp Phe Leu Lys Asp Gly Glu Glu	
785 790 795 800	
gaa acg gta gat tgg agc atc tac ctg tgg gaa gaa aat atc cca aat	2566
Glu Thr Val Asp Trp Ser Ile Tyr Leu Ser Glu Glu Asn Ile Pro Asn	
805 810 815	
aat gca gat acc agt ttc cct tgg gaa tct gta ggt tct gac gcg cct	2614
Asn Ala Asp Thr Ser Phe Pro Ser Glu Ser Val Gly Ser Asp Ala Pro	
820 825 830	

tcc gaa gcg aaa tac gac ctt gcc gaa atg tat ctc gaa atc gcc gac 2662  
 Ser Glu Ala Lys Tyr Asp Leu Ala Glu Met Tyr Leu Glu Ile Gly Asp  
 835 840 845  
 cgc gat gcc gct gcc gag aca gtt cag aaa ttg ctg gaa gaa gcg gaa 2710  
 Arg Asp Ala Ala Ala Glu Thr Val Gln Lys Leu Leu Glu Glu Ala Glu  
 850 855 860  
 gcc gac gta ctc aaa cgt gcc caa gca ttg gcg cag gaa ttg ggt att 2758  
 Gly Asp Val Leu Lys Arg Ala Gln Ala Leu Ala Gln Glu Leu Gly Ile  
 865 870 875 880  
 tga 2761

<210> 2  
 <211> 880  
 <212> PRT  
 <213> Neisseria meningitidis

<400> 2  
 Met Pro Ala Gly Arg Leu Pro Arg Arg Cys Pro Met Met Thr Lys Phe  
 1 5 10 15  
 Thr Asp Cys Thr Arg Ser Asn Arg Ile Gln Pro Pro Thr His Arg Gly  
 20 25 30  
 Tyr Ile Leu Lys Asn Asn Arg Gln Ile Lys Leu Ile Ala Ala Ser Val  
 35 40 45  
 Ala Val Ala Ala Ser Phe Gln Ala His Ala Gly Leu Gly Gly Leu Asn  
 50 55 60  
 Ile Gln Ser Asn Leu Asp Glu Pro Phe Ser Gly Ser Ile Thr Val Thr  
 65 70 75 80  
 Gly Glu Glu Ala Lys Ala Leu Leu Gly Gly Gly Ser Val Thr Val Ser  
 85 90 95  
 Glu Lys Gly Leu Thr Ala Lys Val His Lys Leu Gly Asp Lys Ala Val  
 100 105 110  
 Ile Ala Val Ser Ser Glu Gln Ala Val Arg Asp Pro Val Leu Val Phe  
 115 120 125  
 Arg Ile Gly Ala Gly Ala Gln Val Arg Glu Tyr Thr Ala Ile Leu Asp

130	135	140
Pro Val Gly Tyr Ser Pro Lys Thr Lys Ser Ala Leu Ser Asp Gly Lys 145	150	155 160
Thr His Arg Lys Thr Ala Pro Thr Ala Glu Ser Gln Glu Asn Gln Asn 165	170	175
Ala Lys Ala Leu Arg Lys Thr Asp Lys Lys Asp Ser Ala Asn Ala Ala 180	185	190
Val Lys Pro Ala Tyr Asn Gly Lys Thr His Thr Val Arg Lys Gly Glu 195	200	205
Thr Val Lys Gln Ile Ala Ala Ala Ile Arg Pro Lys His Leu Thr Leu 210	215	220
Glu Gln Val Ala Asp Ala Leu Leu Lys Ala Asn Pro Asn Val Ser Ala 225	230	235 240
His Gly Arg Leu Arg Ala Gly Ser Val Leu His Ile Pro Asn Leu Asn 245	250	255
Arg Ile Lys Ala Glu Gln Pro Lys Pro Gln Thr Ala Lys Pro Lys Ala 260	265	270
Glu Thr Ala Ser Met Pro Ser Glu Pro Ser Lys Gln Ala Thr Val Glu 275	280	285
Lys Pro Val Glu Lys Pro Glu Ala Lys Val Ala Ala Pro Glu Ala Lys 290	295	300
Ala Glu Lys Pro Ala Val Arg Pro Glu Pro Val Pro Ala Ala Asn Thr 305	310	315 320
Ala Ala Ser Glu Thr Ala Ala Glu Ser Ala Pro Gln Glu Ala Ala Ala 325	330	335
Ser Ala Ile Asp Thr Pro Thr Asp Glu Thr Gly Asn Ala Val Ser Glu 340	345	350
Pro Val Glu Gln Val Ser Ala Glu Glu Glu Thr Glu Ser Gly Leu Phe 355	360	365
Gly Gly Ser Tyr Thr Leu Leu Leu Ala Gly Gly Gly Ala Ala Leu Ile 370	375	380
Ala Leu Leu Leu Leu Leu Arg Leu Ala Gln Ser Lys Arg Ala Arg Arg		

WO 00/03003

PCT/GB99/02205

385	390	395	400
Thr Glu Glu Ser Val	Pro Glu Glu Glu	Pro Asp Leu Asp	Ala Ala
405		410	415
Asp Asp Gly Ile Glu	Ile Thr Phe Ala Glu	Val Glu Thr	Pro Ala Thr
420	425		430
Pro Glu Pro Ala Pro	Lys Asn Asp Val	Asn Asp Thr	Leu Ala Leu Asp
435	440		445
Gly Glu Ser Glu Glu	Glu Leu Ser Ala Lys	Gln Thr Phe Asp	Val Glu
450	455		460
Thr Asp Thr Pro Ser	Asn Arg Ile Asp	Leu Asp Phe Asp	Ser Leu Ala
465	470	475	480
Ala Ala Gln Asn Gly	Ile Leu Ser Gly Ala	Leu Thr Gln Asp	Glu Glu
485	490		495
Thr Gln Lys Arg Ala	Asp Ala Asp Trp	Asn Ala Ile Glu	Ser Thr Asp
500	505		510
Ser Val Tyr Glu Pro	Glu Thr Phe Asn Pro	Tyr Asn Pro	Val Glu Ile
515	520		525
Val Ile Asp Thr Pro	Glu Pro Glu Ser	Val Ala Gln Thr	Ala Glu Asn
530	535		540
Lys Pro Glu Thr Val	Asp Thr Asp Phe Ser	Asp Asn Leu Pro	Ser Asn
545	550	555	560
Asn His Ile Gly Thr	Glu Glu Thr Ala Ser	Ala Lys Pro Ala	Ser Pro
565	570		575
Ser Gly Leu Ala Gly	Phe Leu Lys Ala Ser	Ser Pro Glu Thr	Ile Leu
580	585		590
Glu Lys Thr Val Ala	Glu Val Gln Thr Pro	Glu Glu Leu His	Asp Phe
595	600		605
Leu Lys Val Tyr Glu	Thr Asp Ala Val Ala	Glu Thr Ala Pro	Glu Thr
610	615		620
Pro Asp Phe Asn Ala	Ala Ala Asp Asp	Leu Ser Ala Leu	Leu Gln Pro
625	630	635	640
Ala Glu Ala Pro Ser	Val Glu Glu Asn Ile	Thr Glu Thr Val	Ala Glu

645	650	655
Thr Pro Asp Phe Asn Ala Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln		
660	665	670
Pro Ser Glu Val Pro Ala Val Glu Glu Asn Ala Ala Glu Ile Val Ala		
675	680	685
Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Ala Pro Ala Val Glu		
690	695	700
Glu Asn Val Thr Glu Thr Val Ala Glu Thr Ser Asp Phe His Thr Ala		
705	710	715
Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ala Glu Val Pro Ala Val		
725	730	735
Glu Glu Asn Val Thr Lys Thr Val Ala Glu Ile Pro Asp Phe Asn Ala		
740	745	750
Thr Ala Asp Asp Leu Ser Ala Leu Leu Gln Pro Ser Glu Val Pro Ala		
755	760	765
Val Glu Glu Asn Ala Ala Glu Ile Thr Leu Glu Thr Pro Asp Ser Asn		
770	775	780
Thr Ser Glu Ala Asp Ala Leu Pro Asp Phe Leu Lys Asp Gly Glu Glu		
785	790	795
Glu Thr Val Asp Trp Ser Ile Tyr Leu Ser Glu Glu Asn Ile Pro Asn		
805	810	815
Asn Ala Asp Thr Ser Phe Pro Ser Glu Ser Val Gly Ser Asp Ala Pro		
820	825	830
Ser Glu Ala Lys Tyr Asp Leu Ala Glu Met Tyr Leu Glu Ile Gly Asp		
835	840	845
Arg Asp Ala Ala Ala Glu Thr Val Gln Lys Leu Leu Glu Glu Ala Glu		
850	855	860
Gly Asp Val Leu Lys Arg Ala Gln Ala Leu Ala Gln Glu Leu Gly Ile		
865	870	875
		880

&lt;210&gt; 3

&lt;211&gt; 1647

&lt;212&gt; DNA

<213> *Neisseria meningitidis*

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1647)

&lt;400&gt; 3

```

atg aag caa aat gtt atg ttt ctt atc cta ggg cga aat ttt tta aag 48
Met Lys Gln Asn Val Met Phe Leu Ile Leu Gly Arg Asn Phe Leu Lys
  1             5             10            15

att atc cta tgc ttt agt ttt ttt gta cct aaa ttt gca ttg gca tca 96
Ile Ile Leu Cys Phe Ser Phe Phe Val Pro Lys Phe Ala Leu Ala Ser
      20             25             30

gta aat gtt cgg ggt aaa ttt gat agg gtt gaa gtt tat gat gat ggc 144
Val Asn Val Pro Gly Lys Phe Asp Arg Val Glu Val Tyr Asp Asp Gly
      35             40             45

aga tat tta ggt att cga ggt tca gat gac aaa aga aga aga att tgg 192
Arg Tyr Leu Gly Ile Arg Gly Ser Asp Asp Lys Arg Arg Arg Ile Trp
      50             55             60

aaa ggt gta ttt gat aga gaa tcg gga aga tat tta act tca gaa gct 240
Lys Gly Val Phe Asp Arg Glu Ser Gly Arg Tyr Leu Thr Ser Glu Ala
      65             70             75             80

caa gat tta aaa gtt agg cat gta tct act gga gca tca agt acg ggt 288
Gln Asp Leu Lys Val Arg His Val Ser Thr Gly Ala Ser Ser Thr Gly
      85             90             95

aaa gtt agt tcg gtt gta tct tca tca gtt tcc cgc gcc gga gtc ttg 336
Lys Val Ser Ser Val Val Ser Ser Val Ser Arg Ala Gly Val Leu
      100            105            110

gca gga gtc gcc aaa ctt gcc cgc tta ggc gcg aaa tta agc aca agg 384
Ala Gly Val Gly Lys Leu Ala Arg Leu Gly Ala Lys Leu Ser Thr Arg
      115            120            125

gca gtt cct tat gtc gga aca gcc ctt tta gcc cat gac gta tac gaa 432
Ala Val Pro Tyr Val Gly Thr Ala Leu Leu Ala His Asp Val Tyr Glu
      130            135            140

act ttc aaa gaa gac ata cag gca caa ggc tac caa tac gac ccc gaa 480
Thr Phe Lys Glu Asp Ile Gln Ala Gln Gly Tyr Gln Tyr Asp Pro Glu
      145            150            155            160

```



WO 00/03003

PCT/GB99/02205

acc gac aaa ttt gta aaa ggc tac gaa tat agt aat tgc ctt tgg tac	528
Thr Asp Lys Phe Val Lys Gly Tyr Glu Tyr Ser Asn Cys Leu Trp Tyr	
165 170 175	
gaa gac aaa aga cgt att aat aga acc tat ggc tgc tac ggc gtt gac	576
Glu Asp Lys Arg Arg Ile Asn Arg Thr Tyr Gly Cys Tyr Gly Val Asp	
180 185 190	
agt tgc att atg cgc ctt atg tcc gat gac agc aga ttc ccc gaa gtc	624
Ser Ser Ile Met Arg Leu Met Ser Asp Asp Ser Arg Phe Pro Glu Val	
195 200 205	
aaa gaa ttg atg gaa agc caa atg tat agg ctg gca cgt ccg ttt tgg	672
Lys Glu Leu Met Glu Ser Gln Met Tyr Arg Leu Ala Arg Pro Phe Trp	
210 215 220	
aat tgg cat aaa gaa gaa ctg aat aaa tta agt tct ttg gat tgg aat	720
Asn Trp His Lys Glu Glu Leu Asn Lys Leu Ser Ser Leu Asp Trp Asn	
225 230 235 240	
aat ttt gtt tta aat cgt tgc aca ttt aat tgg aat ggc gga gat tgt	768
Asn Phe Val Leu Asn Arg Cys Thr Phe Asn Trp Asn Gly Gly Asp Cys	
245 250 255	
ttg gtc aat aaa ggt gat gat ttc aga aat ggg gct gat ttt tcc ctt	816
Leu Val Asn Lys Gly Asp Asp Phe Arg Asn Gly Ala Asp Phe Ser Leu	
260 265 270	
att cgc aat tca aaa tac aaa gaa gaa atg gat gcc aaa aag ctg gaa	864
Ile Arg Asn Ser Lys Tyr Lys Glu Glu Met Asp Ala Lys Lys Leu Glu	
275 280 285	
gag att tta tgc ttg aaa gtc gat gcc aat ccc gac aaa tac ata aag	912
Glu Ile Leu Ser Leu Lys Val Asp Ala Asn Pro Asp Lys Tyr Ile Lys	
290 295 300	
gaa acc ggt tat ccc ggt tat tcc gaa aaa gta gaa gtc gca ccc gga	960
Glu Thr Gly Tyr Pro Gly Tyr Ser Glu Lys Val Glu Val Ala Pro Gly	
305 310 315 320	
aca aaa gtg aat atg ggt ccc gtc acg gac agg aac ggg aat ccc gtt	1008
Thr Lys Val Asn Met Gly Pro Val Thr Asp Arg Asn Gly Asn Pro Val	
325 330 335	
cag gtt gtc gca aca ttc ggc agg gat tgc caa ggc aac acc acg gtg	1056
Gln Val Val Ala Thr Phe Gly Arg Asp Ser Gln Gly Asn Thr Thr Val	
340 345 350	

WO 00/03003

PCT/GB99/02205

gat gtt caa gta atc ccg cgt ccc gac ttg acc ccc gga agc gcg gaa	1104
Asp Val Gln Val Ile Pro Arg Pro Asp Leu Thr Pro Gly Ser Ala Glu	
355 360 365	
gca ccg aac gca cag ccg ctg ccc gaa gta tcg ccc gcc gaa aac ccc	1152
Ala Pro Asn Ala Gln Pro Leu Pro Glu Val Ser Pro Ala Glu Asn Pro	
370 375 380	
gca aac aac ccg aac ccc aat gag aac ccc ggc acg agc ccc aat ccc	1200
Ala Asn Asn Pro Asn Pro Asn Glu Asn Pro Gly Thr Ser Pro Asn Pro	
385 390 395 400	
gaa ccc gac ccc gat ttg aat ccc gat gca aat ccc gat acg gac gga	1248
Glu Pro Asp Pro Asp Leu Asn Pro Asp Ala Asn Pro Asp Thr Asp Gly	
405 410 415	
cag ccc ggc aca aga ccc gat tcc ccc gcc gtt ccg gga cgc aca aac	1296
Gln Pro Gly Thr Arg Pro Asp Ser Pro Ala Val Pro Gly Arg Thr Asn	
420 425 430	
ggc agg gac ggc aaa gac gga aag gac ggc aaa gat ggc ggc ctt ttg	1344
Gly Arg Asp Gly Lys Asp Gly Lys Asp Gly Lys Asp Gly Gly Leu Leu	
435 440 445	
tgc aaa ttc ttc ccc gac att ctc gct tgc gac agg ctg ccc gag tcc	1392
Cys Lys Phe Phe Pro Asp Ile Leu Ala Cys Asp Arg Leu Pro Glu Ser	
450 455 460	
aat ccg gca gaa gat tta aat ctg ccg tct gaa acc gtc aat gta gag	1440
Asn Pro Ala Glu Asp Leu Asn Leu Pro Ser Glu Thr Val Asn Val Glu	
465 470 475 480	
ttt cag aaa tca gga atc ttt caa gat tcc gca cag tgt ccc gca cct	1488
Phe Gln Lys Ser Gly Ile Phe Gln Asp Ser Ala Gln Cys Pro Ala Pro	
485 490 495	
gtc act ttc aca gtg act gtg ctt gat tca agc agg cag ttc gcg ttc	1536
Val Thr Phe Thr Val Thr Val Leu Asp Ser Ser Arg Gln Phe Ala Phe	
500 505 510	
agc ttt gag aac gca tgt acc ata gcc gaa cgg cta agg tac atg ctt	1584
Ser Phe Glu Asn Ala Cys Thr Ile Ala Glu Arg Leu Arg Tyr Met Leu	
515 520 525	
ctc gcc ctt gct tgg gcg gtt gcc gcc ttt ttt tgt atc cgc aca gta	1632
Leu Ala Leu Ala Trp Ala Val Ala Ala Phe Phe Cys Ile Arg Thr Val	
530 535 540	

WO 00/03003

PCT/GB99/02205

tct cgt gaa gtc tag  
Ser Arg Glu Val  
545

1647

<210> 4  
<211> 548  
<212> PRT  
<213> Neisseria meningitidis

<400> 4  
Met Lys Gln Asn Val Met Phe Leu Ile Leu Gly Arg Asn Phe Leu Lys  
1 5 10 15  
Ile Ile Leu Cys Phe Ser Phe Phe Val Pro Lys Phe Ala Leu Ala Ser  
20 25 30  
Val Asn Val Pro Gly Lys Phe Asp Arg Val Glu Val Tyr Asp Asp Gly  
35 40 45  
Arg Tyr Leu Gly Ile Arg Gly Ser Asp Asp Lys Arg Arg Arg Ile Trp  
50 55 60  
Lys Gly Val Phe Asp Arg Glu Ser Gly Arg Tyr Leu Thr Ser Glu Ala  
65 70 75 80  
Gln Asp Leu Lys Val Arg His Val Ser Thr Gly Ala Ser Ser Thr Gly  
85 90 95  
Lys Val Ser Ser Val Val Ser Ser Ser Val Ser Arg Ala Gly Val Leu  
100 105 110  
Ala Gly Val Gly Lys Leu Ala Arg Leu Gly Ala Lys Leu Ser Thr Arg  
115 120 125  
Ala Val Pro Tyr Val Gly Thr Ala Leu Leu Ala His Asp Val Tyr Glu  
130 135 140  
Thr Phe Lys Glu Asp Ile Gln Ala Gln Gly Tyr Gln Tyr Asp Pro Glu  
145 150 155 160  
Thr Asp Lys Phe Val Lys Gly Tyr Glu Tyr Ser Asn Cys Leu Trp Tyr  
165 170 175  
Glu Asp Lys Arg Arg Ile Asn Arg Thr Tyr Gly Cys Tyr Gly Val Asp  
180 185 190  
Ser Ser Ile Met Arg Leu Met Ser Asp Asp Ser Arg Phe Pro Glu Val

195	200	205
Lys Glu Leu Met Glu Ser Gln Met Tyr Arg Leu Ala Arg Pro Phe Trp 210	215	220
Asn Trp His Lys Glu Glu Leu Asn Lys Leu Ser Ser Leu Asp Trp Asn 225	230	235 240
Asn Phe Val Leu Asn Arg Cys Thr Phe Asn Trp Asn Gly Gly Asp Cys 245	250	255
Leu Val Asn Lys Gly Asp Asp Phe Arg Asn Gly Ala Asp Phe Ser Leu 260	265	270
Ile Arg Asn Ser Lys Tyr Lys Glu Glu Met Asp Ala Lys Lys Leu Glu 275	280	285
Glu Ile Leu Ser Leu Lys Val Asp Ala Asn Pro Asp Lys Tyr Ile Lys 290	295	300
Glu Thr Gly Tyr Pro Gly Tyr Ser Glu Lys Val Glu Val Ala Pro Gly 305	310	315 320
Thr Lys Val Asn Met Gly Pro Val Thr Asp Arg Asn Gly Asn Pro Val 325	330	335
Gln Val Val Ala Thr Phe Gly Arg Asp Ser Gln Gly Asn Thr Thr Val 340	345	350
Asp Val Gln Val Ile Pro Arg Pro Asp Leu Thr Pro Gly Ser Ala Glu 355	360	365
Ala Pro Asn Ala Gln Pro Leu Pro Glu Val Ser Pro Ala Glu Asn Pro 370	375	380
Ala Asn Asn Pro Asn Pro Asn Glu Asn Pro Gly Thr Ser Pro Asn Pro 385	390	395 400
Glu Pro Asp Pro Asp Leu Asn Pro Asp Ala Asn Pro Asp Thr Asp Gly 405	410	415
Gln Pro Gly Thr Arg Pro Asp Ser Pro Ala Val Pro Gly Arg Thr Asn 420	425	430
Gly Arg Asp Gly Lys Asp Gly Lys Asp Gly Lys Asp Gly Gly Leu Leu 435	440	445
Cys Lys Phe Phe Pro Asp Ile Leu Ala Cys Asp Arg Leu Pro Glu Ser		

WO 00/03003

PCT/GB99/02205

450	455	460
Asn Pro Ala Glu Asp Leu Asn Leu Pro Ser Glu Thr Val Asn Val Glu		
465	470	475 480
Phe Gln Lys Ser Gly Ile Phe Gln Asp Ser Ala Gln Cys Pro Ala Pro		
	485	490 495
Val Thr Phe Thr Val Thr Val Leu Asp Ser Ser Arg Gln Phe Ala Phe		
	500	505 510
Ser Phe Glu Asn Ala Cys Thr Ile Ala Glu Arg Leu Arg Tyr Met Leu		
	515	520 525
Leu Ala Leu Ala Trp Ala Val Ala Ala Phe Phe Cys Ile Arg Thr Val		
	530	535 540
Ser Arg Glu Val		
545		



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>C12N 5/08</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/03003</b> <b>(43) International Publication Date:</b> 20 January 2000 (20.01.2000)
<b>(21) International Application Number:</b> PCT/GB99/02205 <b>(22) International Filing Date:</b> 09 July 1999 (09.07.1999) <b>(30) Priority Data:</b> 9814902.4 10 July 1998 (10.07.1998) GB <b>(60) Parent Application or Grant</b> THE UNIVERSITY OF NOTTINGHAM [/]; (). ALA'ALDEEN, Dlawer [/]; (). TODD, Ian [/]; (). ALA'ALDEEN, Dlawer [/]; (). TODD, Ian [/]; (). WOMSLEY, Nicholas ; ().		<b>Published</b>
<b>(54) Title: SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES AGAINST PATHOGENIC NEISSERIA</b> <b>(54) Titre: CRIBLAGE DE CANDIDATS-VACCINS ANTINEISSERIA ET VACCINS CONTRE UNE NEISSERIA PATHOGENE</b>  <b>(57) Abstract</b> <p>Methods of screening for vaccine candidates, vaccines against pathogenic neisseria and intermediaries for such vaccines have been developed. Two vaccine candidates TspA and TspB have been identified and characterised which either alone or in conjunction with the vaccines provide for treatment against pathogenic neisserias in particular Neisseria meningitidis and/or Neisseria gonorrhoea.</p> <b>(57) Abrégé</b> <p>L'invention concerne des méthodes de criblage de candidats-vaccins, des vaccins contre une Neisseria pathogène et des produits intermédiaires utiles pour de tels vaccins. Deux candidats-vaccins TspA et TspB ont été identifiés et caractérisés, lesquels constituent, seuls ou conjointement avec les vaccins, un traitement contre des Neisserias pathogènes, notamment contre Neisseria meningitidis et/ou Neisseria gonorrhoeæ.</p>		



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> C12N 5/08, A61K 39/095, C07K 14/22, C12N 15/31, C12Q 1/68, G01N 33/50	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/03003</b> <b>(43) International Publication Date:</b> 20 January 2000 (20.01.2000)
<b>(21) International Application Number:</b> PCT/GB99/02205 <b>(22) International Filing Date:</b> 09 July 1999 (09.07.1999) <b>(30) Priority Data:</b> 9814902.4 10 July 1998 (10.07.1998) GB <b>(60) Parent Application or Grant</b> THE UNIVERSITY OF NOTTINGHAM [/]; (). ALA'ALDEEN, Dlawer [/]; (). TODD, Ian [/]; (). ALA'ALDEEN, Dlawer [/]; (). TODD, Ian [/]; (). WOMSLEY, Nicholas ; ().	<b>Published</b>	
<b>(54) Title: SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES AGAINST PATHOGENIC NEISSERIA</b> <b>(54) Titre: CRIBLAGE DE CANDIDATS-VACCINS ANTINEISSERIA ET VACCINS CONTRE UNE NEISSERIA PATHOGENE</b>  <b>(57) Abstract</b> <p>Methods of screening for vaccine candidates, vaccines against pathogenic neisseria and intermediaries for such vaccines have been developed. Two vaccine candidates TspA and TspB have been identified and characterised which either alone or in conjunction with the vaccines provide for treatment against pathogenic neisserias in particular Neisseria meningitidis and/or Neisseria gonorrhoea.</p> <b>(57) Abrégé</b> <p>L'invention concerne des méthodes de criblage de candidats-vaccins, des vaccins contre une Neisseria pathogène et des produits intermédiaires utiles pour de tels vaccins. Deux candidats-vaccins TspA et TspB ont été identifiés et caractérisés, lesquels constituent, seuls ou conjointement avec les vaccins, un traitement contre des Neisserias pathogènes, notamment contre Neisseria meningitidis et/ou Neisseria gonorrhoeæ.</p>		

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 5/08, G01N 33 /50, C12Q 1 /68, A61K 39 /095, C07K 14 /22, C12N 15 /31</b>		<b>A3</b>	(11) International Publication Number: <b>WO 00/03003</b>
			(43) International Publication Date: 20 January 2000 (20.01.00)
(21) International Application Number: <b>PCT/GB99/02205</b>		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 July 1999 (09.07.99)		Published <i>With international search report.</i>	
(30) Priority Data: 9814902.4 10 July 1998 (10.07.98) GB		(88) Date of publication of the international search report: 13 April 2000 (13.04.00)	
(71) Applicant (for all designated States except US): THE UNIVERSITY OF NOTTINGHAM [GB/GB]; University Park, Nottingham NG7 2RD (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): ALA'ALDEEN, Dlawer [GB/GB]; The University of Nottingham, University Park, Nottingham NG7 2RD (GB). TODD, Ian [GB/GB]; The University of Nottingham, University Park, Nottingham NG7 2RD (GB).			
(74) Agent: WOMSLEY, Nicholas; Swindell & Pearson, 48 Friar Gate, Derby, DE1 1GY (GB).			
(54) Title: SCREENING OF NEISSERIAL VACCINE CANDIDATES AND VACCINES AGAINST PATHOGENIC NEISSERIA			
(57) Abstract <p>Methods of screening for vaccine candidates, vaccines against pathogenic neisseria and intermediaries for such vaccines have been developed. Two vaccine candidates TspA and TspB have been identified and characterised which either alone or in conjunction with the vaccines provide for treatment against pathogenic neisserius in particular Neisseria meningitidis and/or Neisseria gonorrhoea.</p>			



*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/GB 99/02205

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12N5/08 G01N33/50 C12Q1/68 A61K39/095 C07K14/22  
C12N15/31

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	KIZIL G ET AL: "Identification and characterization of TspA, a major CD4(+) T-cell- and B-cell-stimulating Neisseria-specific antigen." INFECTION AND IMMUNITY, (1999 JUL) 67 (7) 3533-41. , XP002127425 the whole document	1-65,68, 69, 73-76, 78-80
X,P	WO 99 24578 A (PIZZA MARIAGRAZIA ;SCARLATO VINCENZO (IT); RAPPUOLI RINO (IT); CHI) 20 May 1999 (1999-05-20) page 3, line 15 - line 28; claims 4-6,8-17; example 32 page 4, line 7 - line 18 page 5, line 3 - line 16 -/-	61,63, 65,67, 72-78,80

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (see specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

14 January 2000

Date of mailing of the international search report

28/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Charles, D

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 99/02205

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NAESS L M ET AL: "Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine."  INFECTION AND IMMUNITY, (1998 MAR) 66 (3) 959-65. , XP002127426  page 959, column 1, paragraph 1 -column 2, paragraph 1  page 962, column 2, paragraph 1  page 964, column 1, paragraph 4</p>	1-27
A	<p>WIERTZ E J ET AL: "T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins."  INFECTION AND IMMUNITY, (1996 JAN) 64 (1) 298-304. , XP002127427  page 298, column 2, paragraph 2  page 300, column 1, paragraph 1  page 303, column 1, paragraph 1</p>	1-27

Form PCT/ISA210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/ 02205

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 70 and 79 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 99/02205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9924578 A	20-05-1999	AU 9363798 A	31-05-1999